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Abstract
Background: Occurrence of tumors at multiple sites is a hallmark of malignant cancers and
contributes to the high mortality of cancers. The formation of multi-site cancers (MSCs) has
conventionally been regarded as a result of hematogenous metastasis. However, some MSCs may
appear as unusual in the sense of vascular dissemination pattern and therefore be explained by
alternative metastasis models or even by non-metastatic independent formation mechanisms.
Results: Through literature review and incorporation of recent advance in understanding aging
and development, we identified two alternative mechanisms for the independent formation of
MSCs: 1) formation of separate tumors from cancer-initiating cells (CICs) mutated at an early stage
of development and then diverging as to their physical locations upon further development, 2)
formation of separate tumors from different CICs that contain mutations in some convergent ways.
Either of these processes does not require long-distance migration and/or vascular dissemination
of cancer cells from a primary site to a secondary site. Thus, we classify the formation of these
MSCs from indigenous CICs (iCICs) into a new mechanistic category of tumor formation –
multigenesis.
Conclusion: A multigenesis view on multi-site cancer (MSCs) may offer explanations for some
"unusual metastasis" and has important implications for designing expanded strategies for the
diagnosis and treatment of cancers.
Reviewers: This article was reviewed by Carlo C. Maley nominated by Laura F. Landweber and
Razvan T. Radulescu nominated by David R. Kaplan. For the full reviews, please go to the
Reviewers' comments section.
Background
Cancer often appears at multiple sites of the same patient
and such malignancy is associated with the high mortality
of cancer. Except for some systemic cancers such as leuke-
mia [1] and cancers with clear direct anatomic linkages
such as lymphoma [2-4], the conventional view on the
multi-organ occurrence of cancer is that cancer cells leave
a primary tumor site and arrive at one or more different
site(s) to form additional secondary tumor(s) via a com-
prehensive cascading process called metastasis [5,6]. This
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classical cascade includes local migration and invasion,
dissemination through vascular system, entry and coloni-
zation in new environment, and finally proliferation,
such that they out-compete indigenous cells [7].
However, as the last frontier of cancer research, metastasis
is still poorly understood despite over a century of inten-
sive research [8-10]. Towards a better understanding,
investigators in the field of multi-site cancer research cur-
rently focus on the properties of cancer cells that confer
upon them a metastatic capability [11-16].
More recently and importantly, a process preceding cellu-
lar metastasis has been proposed and termed "oncopro-
tein metastasis [17]." This concept is embedded in the
novel "peptide string theory [18-20]" which in turn con-
stitutes an extension of a new physics-based understand-
ing of life: particle biology [20-22].
Moreover, many reports have shown unusual "metastasis"
of cancers which occur at some remote locations that
appear hard to explain by any direct vascular linkage [23-
26]. Thus, in order to have a full understanding of multi-
site cancers, several possible mechanistic aspects for the
cancer formation in multi-sites need to be addressed one
which is considered in this paper.
Hypothesis and rationales
We propose that multigenesis – the formation of cancer in
multiple sites by indigenous cancer initiating cells (iCICs)
– may be a basis for some multi-site cancers (MSCs). Our
hypothesis may be argued on the following theoretical
ground and clinical evidence:
1. From a physicochemical point of view, it is possible
that mutagenic factor(s) can strike multiple cells at differ-
ent body sites and thus independently causes same or dif-
ferent mutations in different cells in different sites. The
presence of multiple mutations in a typical cancer has
been proven by recent genomic screenings in some can-
cers [27]. Although it is unclear which of these mutations
are the main cause for the various cancers it is clear that
the presence of the many different mutations in the differ-
ent body sites could provide a theoretical basis for the for-
mation of independent primary cancer at the multiple
sites.
In the past a "clonal evolution" theory has been used for
explaining the differences observed between "primary"
and "secondary" cancers [28-30]. However, these "site"
differences of the "same" cancers may be a false "conver-
gence" as they may represent truly different cancers
derived from separate cancer-initiating cells. This multi-
genesis of cancer-initiating cells (CICs) may also explain
why there was even some "unexpectedly high genetic
divergence" in "minimal residual cancer [31]."
We should also point out that the parallel mutagenesis for
multigenesis of anatomically separate cancers is different
from "the parallel evolution model" for metastasis [32].
In the latter model, it is hypothesized that the differences
found between primary and secondary tumors [33], espe-
cially those solid tumors [34], are results of parallel but
different evolution of the same cancers cells whose metas-
tasis have occurred earlier [35].
Since the term "mutation" could conceivably be extended
to include not just the mutation in the protein-encoding
DNA sequence but also a modification in the epigenetic
status of the DNA, the structure of a chromosome, and the
conformation of a protein, the latter of which may trans-
late into a "conformational mutation" correlating with a
loss of function [36], it is possible that at least one of these
distinct types of mutations could independently occur in
cells at multiple sites. The sharing of a common underly-
ing mutation mechanism may yield an apparent "conver-
gent" phenotype to the separate tumors derived from a
common type of mutation. But these independent cancers
would be by no means a result of any "metastasis" because
they do not share a common ancestor cancer-initiating
cell (CIC).
2. From a development perspective [37], it is very likely a
cell mutated earlier in embryogenesis may contribute to
the formation of multi-organ cancers when its offspring
cells inheriting the same mutation migrate to different
sites to form other tissues in the different organs. In other
words, a "jackpot" (gestational) mutation [38] early in
development may produce mutant cells that end up in dif-
ferent organs. This formation of multi-site cancer due to
this developmental separation of mutated cells is different
from the conventional metastasis because the mutated
cells are truly indigenous to the various organs at the time
of their formation. As a matter of fact, many stem cell can-
cers [39-41] may be called multigenesis cancers rather
than metastasis cancers.
We noticed that the "same gene model" actually holds this
same view that genetic alterations can be acquired early in
carcinogenesis [42]. But that model has been mainly used
for explaining the resemblance of gene expression signa-
ture [43,44] or genetic alterations [45] between primary
and "secondary" cancers under a predetermined assump-
tion of "metastasis" [42,45]. However, as we argued in the
first point, the same gene can be mutated in anatomically
separate cells, leading to the multigenesis of different can-
cers that does not share any direct vascular connection.Biology Direct 2008, 3:14 http://www.biology-direct.com/content/3/1/14
Page 3 of 11
(page number not for citation purposes)
3. From an aging perspective [46-48], it is very likely the
same aging process may result in genetic and/or epige-
netic damages to DNA or other molecules in cells located
in the different parts of the body which then contribute to
the independent origin of CICs and thus non-metastatic
MSCs [37,49,50]. This parallelism in cell lineage develop-
ment, in similarity to the parallelism observed in evolu-
tion [51,52], predict that a common aging-mechanism-
based carcinogenesis may explain not only why cancers
often occur at the older ages but also why older people
tend to have multiple cancers [50,53]. The detailed
hypothesis of a linkage between DNA molecule aging and
cell aging [46] and the existence of such aging axis from
molecule to cell and to multicellular organism [37] may
provide a foundation for drawing a roadmap for not only
normal development but also some abnormal processes
[50]. To illustrate how environmental factors can disturb
the living processes in various ways and thus contribute to
the formation of multi-site cancers, we schematically
depict some key aspects of carcinogenesis over a repre-
sentative life span (Fig. 1).
4. From a pathological point of view, "primary" tumors of
"metastatic cancers" are often identified at the easily
observable or life-threatening sites while "secondary"
tumors of "metastatic cancers" are often detected at sites
that are either difficult to be discovered or not critical to
influence the normal life. It is logically hard to argue why
the primary occurrence of carcinogenesis often happens in
those easily observable and/or life-threatening sites. This
argument is even more difficult to be accepted when the
carcinogenic cells in the multiple organs are of the same
tissue type and even the same cell type. However, it would
make more sense to explain the apparent time-lagging
between these "primary" and "secondary tumors as a
result of either the different growth rates of the same can-
cer cells in the different sites or the different detection
rates of the same tumor at the different sites or a combi-
nation of both factors. Thus, the growth of tumors at the
different sites and the understanding of cancer dormancy
or latency [54] is not only related with the difference in
"soils" but also the difference in "seeds".
5. From recent understanding of genome organization it is
clear that genomes are composed of various modules
[55,56]. Theoretically, independent mutations can hap-
pen by a common mechanism on the same type of DNA
module that contributes to different genes or genes' regu-
latory elements. As a matter of fact, more and more evi-
dences are accumulating to support this mechanism of
multi-gene and multi-site mutations/alterations in
genome and the subsequent cancer formation [57-60].
Thus, rather starting a series of primary-secondary cancers
from one mutation in one cell, multi-site cancers can orig-
inate from multiple mutations/alterations on the same
genes/genome locations or the same module in different
genes. Indeed, recent studies have shown that the same
transformation in different cell types leads to distinct
tumor phenotypes [61]. Moreover, recent studies have
also shown the existence of common mutated genes
between breast and colorectal cancers [27,62]. This new
information may offer an explanation for the increased
prevalence of colorectal cancer in breast cancer patients
[63-73] that was observed much earlier [74-79]. Better
understanding of the genetics of colorectal and breast can-
cer [80] and the developmental lineage of the cancer cells
in these two major cancers may offer some insight on the
true mechanism of the formation of these often related
prevalent multi-site cancers.
6. From clinical observations, we have noticed many
reports of so-called unusual "metastasis" of cancers. For
example, there have been some report of multi-site can-
cers buried in solid tissue mass but the other easy-to-
spread sites often lack such cancer [23-26]. Interestingly,
despite the "unusual" nature of these multi-site cancers,
the pairing between the "primary" and the "secondary"
tumors in some of these rare "metastasis" cases is very
consistent [81,82].
7. Some studies have shown that the locations of distant
secondary tumors in many clinical cancers and animal
tumors are nonrandom, and their distributions cannot be
explained by simple anatomical or mechanical hypothe-
ses based on the simple lodgment or trapping of tumor
cell emboli in the first capillary bed encountered [83].
These observations were used for the argument that the
unique properties of particular tumor cells ('seeds') and
the different characteristics of each organ microenviron-
ment ('soil') collectively determine the organ preference
of metastasis [83], without, however, advancing additional
mechanistic models.
8. Some earlier studies actually have provided evidence
that the occurrence of some multiple tumors (MTs) is not
due to migration of tumor cells because the tumor cells in
different sites are not clonally related [84,85] based on the
use of some "clonal" markers [86,87]. However, the use of
identity or similarity in "clonal" markers as the only dif-
ferentiation criterion for distinguishing clonally linked or
independent tumor/cancer formation may be misleading.
This is because similarity is not always the result of a com-
mon origin. That notion is based on the statistical asser-
tion that highly similar patterns in "clonal" markers are
unlikely when the mutation is random. However, the very
possible truth is that mutation is not random at all. Thus,
it is formally possible that the same or similar mutation
can happen in multiple cells and yield CICs with similar
or even identical "clonal" markers. Thus, the incidence ofBiology Direct 2008, 3:14 http://www.biology-direct.com/content/3/1/14
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Schematic representation of multi-site cancer formation by multigenesis and how to distinguish multigenesis from metastasis Figure 1
Schematic representation of multi-site cancer formation by multigenesis and how to distinguish multigenesis 
from metastasis. Germ (G), stem (S), progenitor (P) and terminal (T) cells are represented by solid, crossed, slashed and 
hollow circles, respectively. Subsequent to a mutation that changes a normal cell (without slash across the circle) into a cancer 
cell (with a slash across the circle), depending on the nature of cancer-initiating cells (CICs), the clones (encircled by a dashed 
polygon) may contain different compositions of cells at different differentiation stages. There is also some intrinsic cell age het-
erogeneity in all clones which is indicated in one way by showing the generation succession with solid arrow lines. The contin-
ued existence of the mother cell over the different development stages is indicated by dashed arrow lines as shown for 
germline cells. A mutation in a germ cell may pass into offspring if it occurs at any pre-senescent stage. The distinction between 
a cancer cell translocated from a primary tumor site (site A) to a secondary site (site B) and a cancer cell originated from an 
indigenous cell in the same site (site B) may be made by determining a difference in mutations and/or in cell age even if the cells 
are otherwise genetically identical. Alternatively, an artificial marker may be introduced into offspring cells of the CICs during 
their reproduction in a primary cancer site so that these cells are distinct (indicated by a thick slash across the circle) from the 
rest. This experimental approach may offer a way to distinguish metastatic cancer cells from indigenous cancer cells even if 
they share the same mutations due to a convergence in the mechanisms of carcinogenesis. The growth of tumors at the differ-
ent sites may be influenced by the environmental conditions at the different sites so that differential tumor growth rates can be 
seen even for the same CICs. In addition, metastatic cancer cells may have different fates at the different "soils"; some may 
establish and proliferate while some may die (as indicated by double heavy slashes). These complexities of multi-site cancers 
are selectively represented in the diagrams, too.Biology Direct 2008, 3:14 http://www.biology-direct.com/content/3/1/14
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MPTs or MPCs might have been underestimated by the
"clonal" marker in these analyses.
The occurrence of some (anatomically adjacent) multiple
primary tumors (MPTs) [88] or multiple primary cancers
(MPCs) [89,90] have been explained by a field cancerisa-
tion theory [91,92]. In this theory, the initial mutagenesis
happens not just in one cell but a whole tract of tissue – a
"field". These mutated progenitor cells then spread and
cause independent tumors [93]. Thus, field cancerisation
could alternatively be interpreted as local multigenesis. By
extension, multigenesis should also be possible in distant
and separated "fields", thus contributing to the formation
of MPTs or MPCs bearing no anatomical relationship.
9. Therapies aimed at eradicating metastasis cancer cells
often do not change much the progress of the cancer and
the life expectancy of cancer patients [94,95]. This may
indicate that cutting off the vascular "connections" among
primary and "secondary" tumors may not be sufficient for
treating all the "secondary" tumors. Most likely, some of
the so-called "secondary" tumors are independent pri-
mary tumors which may contain either dormant cancer
cells that resist systematic cancer therapy or active cancer
cells which escape the killing due to that fact that their
reproduction time is outside the treatment window
[96,97].
Implications and impact
We should emphasize that our proposal of a multigenesis
mechanism for the occurrence of multi-site cancer does
not dispute the occurrence of metastasis which may be
even the prevalent cause for many of the multi-site cancers
[98-100]. In some cases, the multi-site cancers in a patient
may reflect the outcomes of both processes [85]. How-
ever, embracing a multigenesis view of multi-site cancer
formation may provide additional insights into a compre-
hensive understanding of the cancer biology and thor-
ough guidance on cancer therapy.
If multigenesis is also a mechanism for the formation of
multi-site cancer, then a more proactive diagnosis screen-
ing should be implemented even if the incidentally found
"primary" cancer is in the very early stage. However,
instead of random search, these earlier and broader scope
screening may be focused more on the tissues that share
the same lineages with the cancer cells in the already
found "primary" site.
In the past arguments on metastasis cancers or multiple
primary cancers have been focused on whether the muta-
tions in the cancer cells of the different sites are similar or
not. These arguments are based on a rationale that ran-
dom mutation rarely leads to the identical or highly simi-
lar mutations in different cells. While these arguments
may be true, a better and more definite criterion in sepa-
rating metastatic cancer from multigenesis cancer may be
the distinction of the age of the cancer-initiating cells in
each sites. If the CICs at the two different sites have the
same or very similar old chronological age then they are
more likely originated from independent mutations. By
"old" we mean that the CICs have lived longer time than
the first discovery of even the primary tumor.
If the multi-site cancers in a patient are originated with
multigenesis, the treatment should not just be focused on
the first found "primary" cancer site at the later stages or
at the easy to be seen location but also be proactively
extended into other likely primary sites. On the other
hand, the application of cancer treatment need not to be
carried out via any systemic way so that more normal
reproducing cells could be saved from the non-discrimi-
native killing by the current cancer treatment options. As
a matter of fact, studies have shown that systematic treat-
ment damage immune cells in addition to some cancer
cells and thus make the patients weaker in dealing with
the spared cancers cells once these cancer cells come back
to life or proliferation [96,97].
Ideally, highly-targeted cancer drugs should be developed
that will be effective only at those proliferating cells bear-
ing the cancer biomarker(s). Certainly, different cancer
cells originally from different points of cell lineage forma-
tion may have their different biomarkers and thus even
cancer drugs themselves should be tailored for the differ-
ent types of cancers [101].
Yet, the development of cancer is not just a "seed" prob-
lem but also a "soil" challenge [8,102,103]. Given that
cancer "seeds" could be formed through multiple routes
[104,105] and come in as a result of some early spread
[106], an effective cancer therapy should also include pre-
venting the "soil"-more precisely, morphologically nor-
mal, yet likely premalignant cells-from undergoing
oncoprotein-driven malignant transformation [17,107-
109].
On the other hand, even some bad "seeds" could conceiv-
ably be "corrected" as some (cancer) stem cells appear to
be highly moldable and, as such, could be artificially re-
directed into some normal development [110-112].
Furthermore, inducing a good soil should not only curtail
the growth of bad seeds but also prevent their recurrence
[113]. But such good "soils" are difficult to maintain
when current non-discriminating systemic cancer therapy
destroys many normal cells, too. Thus, overcoming the
non-discriminating nature of such classical cancer therapy
is a high priority in improving the treatment effectiveness.Biology Direct 2008, 3:14 http://www.biology-direct.com/content/3/1/14
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In cancer research, cancer biology should be linked more
closely with developmental biology so that the non-met-
astatic linkages between many "unusual" multi-organ
cancers can be found by their underlying cell lineage links
in development. With this scientific insight and with the
power of genomic and other omic technologies [114],
biomarkers for the different series of multi-site cancers
may be found and used for early detection of multi-site
cancers [115,116]. However, cautions should be exerted
in differentiating biomarkers for metastasis and biomark-
ers for multigenesis.
Conclusion
Multi-site occurrence is the hallmark of the high-grade
malignancy cancer and often constitutes the final deadly
blow to the patient's life. While metastasis is definitely
true for the occurrences of many multi-site cancers [98-
100], alternative mechanisms may also exist and deserve
attention. The multigenesis hypothesis proposed in this
paper may explain some "unusual" occurrences of multi-
site cancers. When this perspective on cancer is combined
with increasing knowledge of cell lineage formation in
hierarchical multicellular organisms [37] more precise
predictions on the likely occurrence of multi-site cancers
could possibly be made. This multigenesis view of cancer
should also lead to an expanded perspective on cancer
therapy which may result in the development of more
selective medicines that are not only cancer subtype-spe-
cific and thus more effective but also less damaging to
non-cancer cells.
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Reviewer 2: Carlo C. Maley, The Wistar Institute, 
Philadelphia, Pennsylvania, USA
In most of cancer biology, the appearance of multiple
neoplasms in different sites is assumed to have been gen-
erated by a primary tumor that has metastasized to sec-
ondary sites. Zhang et al. have proposed two alternative
hypotheses: 1) A "jackpot" (gestational) mutation [38]
early in development may produce mutant cells that end
up in different organs. 2) Coincidental, convergent but
independent evolution of neoplasms at separate sites.
Zhang et al. do not claim that these hypotheses explain all
or even most cases of multi-site neoplasms, but may
explain some "unusual metastasis" cases, especially those
in which neither the lymph system nor the vasculature can
easily explain how metastatic cells might travel from one
site to the other. The unusual metastases are the key to the
author's arguments and should be expanded upon (there
must be other cases aside from the intracardiac cases men-
tioned).
These hypotheses are interesting and may be correct, but
there is more evidence that should be marshaled in order
to convince the community. The two hypotheses make
testable predictions, some of which may be addressed
through the literature. If neoplasms derive from a jackpot
mutation in development then there should be some con-
straints on which sites would share the mutant clone due
to cell lineage fates. In the cases that cannot easily be
explained by metastasis, are the sites more often related by
development than would be expected by chance? (they
authors should review the limited literature on gestational
mutations in cancer [38]). If the mutant happened early
enough in development to be found in multiple sites,
then that clone would probably expand to a fairly large
size in both organs, just by normal development (let
alone neoplastic clonal expansion). So we would expect
to find a large, probably pre-cancerous, patch in both
sites. Hereditary cancer syndromes are extreme cases of
this hypothesis. Retinoblastoma can show up independ-
ently in both eyes, but only in children that have inherited
an inactive allele of Rb [39].
The convergent evolution hypothesis should also be easy
to study because genotyping of the independent sites
should reveal if they are clonally related. While some of
the same genes might be activated/inactivated in inde-
pendent tumors, it is highly unlikely that the exact same
point mutation, or the boundaries would be the same on
a region of loss of heterozygosity (LOH), deletion or
amplification between independent neoplasms. Mito-
chondrial mutations, X-inactivation and microsatellite
shifts, and even cytokeratins [31] have also been used to
test clonality. A number of studies have looked at the rela-
tionship between primary tumors and (putative) metas-
tases and found evidence of clonality [30,45]. I do not
know if this has ever been done on "unusual metastases."
If the authors have access to an unusual metastasis, it wold
only take 3 SNP arrays (normal and the two sites) to deter-
mine if the tumors carry the same or independent LOH
lesions. Another prediction of the convergent evolution
hypothesis is that the same mutations are selectively
advantageous to a clone in the two different sites. OneBiology Direct 2008, 3:14 http://www.biology-direct.com/content/3/1/14
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could imagine testing this in an orthotopic xenograft
model in which cells of the correct type and with the
mutation are injected into the appropriate organ and their
fate is tracked. Similarly, there are now inducible genetic
models in which a minority of cells in an organ may be
genetically manipulated.
Authors' response
This is a very careful and helpful review. We have
addressed the issues raised by making significant changes
and enhancements which include:
"In the past a "clonal evolution" theory has been used for
explaining the differences observed between "primary"
and "secondary" cancers [28-30]. However, these "site"
differences of the "same" cancers may be a false "conver-
gence" as they may represent truly different cancers
derived from separate cancer-initiating cells. This multi-
genesis of cancer-initiating cells (CICs) may also explain
why there was even some "unexpectedly high genetic
divergence" in "minimal residual cancer" [31].
We should also point out that the parallel mutagenesis for
multigenesis of anatomically separate cancers is different
from "the parallel evolution model" for metastasis [32].
In the latter model, it is hypothesized that the differences
found between primary and secondary tumors [33], espe-
cially those solid tumors [34], are results of parallel but
different evolution of the same cancers cells whose metas-
tasis have occurred earlier [35]."
"We noticed that the "same gene model" actually holds
this same view that genetic alterations can be acquired
early in carcinogenesis [42]. But that model has been
mainly used for explaining the resemblance of gene
expression signature [43,44] or genetic alterations [45]
between primary and "secondary" cancers under a prede-
termined assumption of "metastasis" [42,45]. However,
as we argued in the first point, the same gene can be
mutated in anatomically separate cells, leading to the
multigenesis of different cancers that does not share any
direct vascular connection."
"In the past arguments on metastasis cancers or multiple
primary cancers have been focused on whether the muta-
tions in the cancer cells of the different sites are similar or
not. These arguments are based on a rationale that ran-
dom mutation rarely leads to the identical or highly simi-
lar mutations in different cells. While these arguments
may be true, a better and more definite criterion in sepa-
rating metastatic cancer from multigenesis cancer may be
the distinction of the age of the cancer-initiating cells in
each site. If the CICs at the two different sites have the
same or very similar old chronological age then they are
more likely originated from independent mutations. By
"old" we mean that the CICs have lived longer time than
the first discovery of even the primary tumor. "
The publications referred by this peer reviewer are inte-
grated into this revision and thus we added the citation
numbers in the above review accordingly.
Reviewer 3: Razvan T. Radulescu, Molecular Concepts 
Research (MCR), Munich, Germany
In their theoretical study entitled "Occurrence of cancer at
multiple sites: Metastasis versus multigenesis?" and sub-
mitted to Biology Direct, Zhang et al. propose that de novo
initiation of cancer in multiple sites may actually account
for those clinical cases in which metastasis to "unusual"
sites has been ascertained. Yet, one should caution that, as
already revealed by the seminal work of Garth Nicolson
and associates (cf. e.g. Cancer Metastasis Rev. 1988; 7:
143–188), metastatic distributions cannot be explained
just by anatomical or mechanical considerations based on
the trapping of tumor cells in the first capillary bed along
their migratory route, therefore ruling in that "unusual"
sites can still be compatible with the process of metastasis.
Nevertheless, the above hypothesis by Zhang et al. would
have merit to be published provided that it was revised
along the following lines. Rather than replacing a valid
concept by another, the presented arguments are better
suited to explain the well-known, but still unclear multi-
genesis phenomenon per se, specifically those rare, yet sig-
nificant clinical cases in which a multiple occurrence of
carcinomas can be observed in the same tissue or yet in
distinct tissues, the so-called multiple primary tumors
(MPT).
Since these (clonally distinct, cf. e.g. the Cancer reports by
Monique van Oijen et al., 2000; 88: 884–893 and by
Winand Dinjens et al., 2003; 97: 1766–1774) neoplasias
are most likely induced by adverse/toxic environmental
influences (such as cigarette smoke or distinct carcino-
genic chemicals) and, moreover, their occurrence may be
precipitated by progressive aging, the published hypothe-
sis by Shi V. Liu linking the possibility of an asymmetric
segregation of DNA strands during DNA replication
(whereby the retained DNA strand in the aging cell accu-
mulates an increasing amount of epigenetic modifications
as a result of various environmental exposures) with both
cancer and senescence- to which the manuscript by Zhang
et al. refers on page 2-ought to be described in further
detail as a potentially important mechanism accounting
for the independent occurrence of primary neoplasias at
multiple sites. In this context, an explanatory diagram
would be helpful.
Moreover, the title of the paper should be amended
accordingly, e.g. to read "Occurrence of cancer at multipleBiology Direct 2008, 3:14 http://www.biology-direct.com/content/3/1/14
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sites: Distinguishing multigenesis from metastasis", the
word "better" deleted from the background and conclu-
sion sections of the abstract on page 1 and the abstract
revised such as to reflect the above suggested shift in con-
ceptual focus on providing a mechanistic basis for the
occurrence of MPTs.
Finally, I am aware of the fact that the currently prevailing
opinion in cancer therapeutics is to molecularly target
individual tumors while sparing (morphologically) nor-
mal cells. This is reflected by the following passage in the
manuscript by Zhang et al.: "If multigenesis is the cause
for a multi-site cancer, the application of cancer treatment
need not to be carried out via any systemic way but could
be made at specific site(s) so that more normal reproduc-
ing cells could be saved from the non-discriminative kill-
ing by the current cancer treatment options. More ideally,
highly-targeted cancer drugs may be developed that will
be effective only at those proliferating cells bearing the
cancer biomarker(s). Certainly, different cancer cells orig-
inally from different points of cell lineage formation may
have their different biomarkers and thus even cancer
drugs themselves should be tailored for the different types
of cancers [64]."
By contrast, I have developed a novel concept over the
past years (cf. Logical Biol. 2005; 5: 17–29 and 87–88 as
well as arXiv:0711.4743) according to which, similar to
the natural interferon-based protection of non-infected
cells during a viral infection, new anti-cancer drugs should
not only be directed against neoplastic cells, but also be
designed such as to equally prevent normal cells from
being transformed and thus ultimately to avert metastasis
including what I coined as "oncoprotein metastasis" (cf.
arXiv:0712.2981 and Proc. Natl. Acad. Sci. USA 2008, doi/
10.1073/pnas.0712232105) or yet, as I specify here, the
emergence of MPTs. Towards accelerating future progress
in this area, it may therefore be fruitful if Zhang et al.
touched upon the existence and potential of this pub-
lished alternative view on treating cancer in their revision
accordingly.
Authors' response
This is a very solid and constructive review. We have
addressed the issues raised by making significant changes
and enhancements in the revised version. The major
changes made in this revision include:
"More recently and importantly, a process preceding cel-
lular metastasis has been proposed and termed "oncopro-
tein metastasis"[17]. This concept is embedded in the
novel "peptide string theory" [18-20] which in turn con-
stitutes an extension of a new physics-based understand-
ing of life: particle biology [20-22].
Moreover, many reports have shown unusual "metastasis"
of cancers which occur at some remote locations that
appear hard to explain by any direct vascular linkage [23-
26]. Thus, in order to have a full understanding of multi-
site cancers, several possible mechanistic aspects for the
cancer formation in multi-sites need to be addressed one
which is considered in this paper."
"Since the term "mutation" could conceivably be
extended to include not just the mutation in the protein-
encoding DNA sequence but also a modification in the
epigenetic status of the DNA, the structure of a chromo-
some, and the conformation of a protein, the latter of
which may translate into a "conformational mutation"
correlating with a loss of function [36], it is possible that
at least one of these distinct types of mutations could
independently occur in cells at multiple sites. The sharing
of a common underlying mutation mechanism may yield
an apparent "convergent"  phenotype to the separate
tumors derived from a common type of mutation. But
these independent cancers would be by no means a result
of any "metastasis" because they do not share a common
ancestor cancer-initiating cell (CIC)."
"The detailed hypothesis of a linkage between DNA mol-
ecule aging and cell aging [46] and the existence of such
aging axis from molecule to cell and to multicellular
organism [37] may provide a foundation for drawing a
roadmap for not only normal development but also some
abnormal processes [50]. To illustrate how environmental
factors can disturb the living processes in various ways
and thus contribute to the formation of multi-site cancers,
we schematically depict some key aspects of carcinogene-
sis over a representative life span (Fig. 1)."
"Some studies have shown that the locations of distant
secondary tumors in many clinical cancers and animal
tumors are nonrandom, and their distributions cannot be
explained by simple anatomical or mechanical hypothe-
ses based on the simple lodgment or trapping of tumor
cell emboli in the first capillary bed encountered [83].
These observations were used for the argument that the
unique properties of particular tumor cells ('seeds') and
the different characteristics of each organ microenviron-
ment ('soil') collectively determine the organ preference
of metastasis [83], without, however, advancing additional
mechanistic models.
Some earlier studies actually have provided evidence that
the occurrence of some multiple tumors (MTs) is not due
to migration of tumor cells because the tumor cells in dif-
ferent sites are not clonally related [84,85] based on the
use of some "clonal" markers [86,87]. However, the use of
identity or similarity in "clonal" markers as the only dif-
ferentiation criterion for distinguishing clonally linked orBiology Direct 2008, 3:14 http://www.biology-direct.com/content/3/1/14
Page 9 of 11
(page number not for citation purposes)
independent tumor/cancer formation may be misleading.
This is because similarity is not always the result of a com-
mon origin. That notion is based on the statistical asser-
tion that highly similar patterns in "clonal" markers are
unlikely when the mutation is random. However, the very
possible truth is that mutation is not random at all. Thus,
it is formally possible that the same or similar mutation
can happen in multiple cells and yield CICs with similar
or even identical "clonal" markers. Thus, the incidence of
MPTs or MPCs might have been underestimated by the
"clonal" marker these analyses.
The occurrence of some (anatomically adjacent) multiple
primary tumors (MPTs) [88] or multiple primary cancers
(MPCs) [89,90] have been explained by a field cancerisa-
tion theory [91,92]. In this theory, the initial mutagenesis
happens not just in one cell but a whole tract of tissue – a
"field". These mutated progenitor cells then spread and
cause independent tumors [93]. Thus, field cancerisation
could alternatively be interpreted as local multigenesis. By
extension, multigenesis should also be possible in distant
and separated "fields", thus contributing to the formation
of MPTs or MPCs bearing no anatomical relationship."
"Yet, the development of cancer is not just a "seed" prob-
lem but also a "soil" challenge [8,102,103]. Given that
cancer "seeds" could be formed through multiple routes
[104,105] and come in as a result of some early spread
[106], an effective cancer therapy should also include pre-
venting the "soil"-more precisely, morphologically nor-
mal, yet likely premalignant cells-from undergoing
oncoprotein-driven malignant transformation [17,107-
109]."
We have changed the title and revised the abstract by tak-
ing into this reviewer's suggestions. We also added a figure
to schematically show the occurrence of multi-site cancers
by multigenesis and how it can be distinguished from
metastasis.
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